Satellite Banner
Scientific Community
Become a Member | Sign in
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
Detecting When Hormone Treatment for Breast Cancer Stops Working
Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment.
Packaging and Unpacking of the Genome
New research improves understanding of the importance of histone replacement.
New Way to Find DNA Damage
University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders.
How Different Treatments for Crohn's Effect the Microbiome
Different treatments for Crohn's disease in children affects their gut microbes in distinct ways, which has implications for future development of microbial-targeted therapies for these patients, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
Charting the 'Genomic Biography' of Leukemia
A new study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard offers a glimpse of the wealth of information that can be gleaned by combing the genome of a large collection of leukemia tissue samples.

Biomarkers in Late-Stage Clinical Trials: Applications, opportunities and activities of leading players
Bookmark and Share

Biomarkers reduce the attrition rate of late-stage clinical trials by assessing drug potential in terms of efficacy and toxicity at the early stages of clinical development. Thus, biomarkers significantly increase productivity, lower the cost and duration of clinical trials, and help researchers complete the drug development process at a faster pace.

Scope of this research

  • Assessment of the revenues of late-stage biomarker technology and services in North America, Europe, Asia and the rest of the world.
  • Details of the key market drivers and restraints in the biomarker sector.
  • Information about microarrays, immunoassay, LC/MS and GC/MS, flow cytometry, imaging, PCR and services.
  • Patent analysis with respect to competitors and geography.
  • Discussion of major pharmaceutical companies, biotechs, contract research organizations and biomarker specialists.

Research and analysis highlights

The pharmaceutical and biotech sectors are currently facing increasing duration and cost issues related to clinical trials in drug discovery. Funding from government sources such as the National Institutes of Health has not increased significantly over the last few years.

More than 50% of clinical trials fail in Phase III for a host of reasons, including greater disease complexity, stiffer clinical endpoints, and the inability of the data to prove drug effectiveness.

Biomarkers play a crucial role in late-stage clinical trials by acting as surrogate endpoints for patient monitoring and stratification. Surrogate endpoints help measure treatment efficacy, and thus facilitate significant cost reductions in the drug development process.

Key reasons to purchase this research

  • Examine and evaluate the growth potential of emerging technologies.
  • Understand biomarker activity in the clinical trials of leading market players.
  • Gain knowledge about the relative importance of biomarker late-stage clinical trials technologies over the next five years.
  • Determine the collaborations and partnerships of the major market players.

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos